

## **NZX Announcement**

18 May 2020

### **Notice of Offer of Same Class Financial Products for Issue**

Truscreen Limited (“Truscreen”) intends to undertake an offer of up to a maximum of 30,000,00 new ordinary fully paid shares at an issue price of \$0.05 per share to members of the public (“the Offer”).

Pursuant to clause 20 of Schedule 8 of the Financial Markets Conduct Regulations 2014 (“Regulations”) and clause 19 of Schedule 1 of the Financial Markets Conduct Act 2013 (“FMCA”), TRU advises that:

1. The Offer is being made in reliance upon the exclusion in clause 19 of Schedule 1 of the FMCA. Truscreen is giving this notice (Cleansing Notice) under clause 20(1)(a) of Schedule 8 of the Regulations.
2. As at the date of this Cleansing Notice, Truscreen is in compliance with:
  - (a) the continuous disclosure obligations that apply to it in relation to Truscreen’s quoted financial products; and
  - (b) its “financial reporting obligations” (within the meaning set out in clause 20(5) of Schedule 8 of the Regulations).
3. As at the date of this Cleansing Notice, there is no information that is “excluded information” within the meaning set out in clause 20(5) of Schedule 8 of the Regulations.
4. The Offer is not expected to have any material effect or consequences on the control of Truscreen.

On behalf of the Board,



**Guy Robertson**  
**Chief Financial Officer**

For more information, visit [www.truscreen.com](http://www.truscreen.com) or contact:

### TruScreen

Victoria Potarina  
Chief Executive Officer  
[victoriapotarina@truscreen.com](mailto:victoriapotarina@truscreen.com)

Guy Robertson  
Chief Financial Officer  
[guyrobertson@truscreen.com](mailto:guyrobertson@truscreen.com)

### About TruScreen:

TruScreen is a Cervical Cancer Screening Device which offers the latest technology in cervical screening, providing real-time, accurate detection of pre-cancerous and cancerous cervical cells to help improve the health and well-being of women around the world. TruScreen's real-time cervical cancer technology utilises a digital wand which is placed on the surface of the cervix to measure electrical and optical signals from the surrounding tissues. A sophisticated proprietary algorithm framework is utilised to detect pre-cancerous change, or cervical intra-epithelial neoplasia (CIN), by optical and electrical measurement of cervical tissue.



TruScreen offers an alternative approach to cervical screening, resolving many of the ongoing issues with Pap tests, including failed samples, poor patient follow-up, patient discomfort and the need for supporting laboratory infrastructures. As such, TruScreen's target market is low- and middle-income countries where no large-scale cervical cancer screening programs and infrastructure are in place, such as China, Mexico, Africa, Russia and India. TruScreen's cervical cancer screening device is CE-marked and certified for use throughout Europe and CFDA-approved for sale in China. The global market potential for TruScreen is significant.

For more information, visit our website at [www.truscreen.com](http://www.truscreen.com)

Watch our video on TruScreen: <http://truscreen.com/truscreen-the-company/truscreen-ultra-video/>